More BET Publications and New Indications

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

More BET Publications and New Indications

posted on Dec 28, 2018 05:14PM

A great post by General360 over on Stockhouse on new BET publications and new indications. Not really relared to Resverlogix ongoing programs; more related to pan BET inhibitors, Zenith and oncology. Thanks General!